Apparatus and methods are described for use with a portion of plant material that includes at least one active ingredient. A vaporizing unit includes a heating element configured to heat the plant material, and a sensor configured to detect an indication of airflow rate through the vaporizing unit. Control circuitry is configured to receive an indication of the airflow rate through the vaporizing unit, and, in response thereto, to determine a smoking profile that is desired by the user. The control circuitry drives the heating element to vaporize the active ingredient of the plant material by heating the plant material according to the determined smoking profile. The control circuitry dynamically updates the smoking profile in response to changes in airflow rate over the course of a smoking session. Other applications are also described.

A monitoring system includes a weight sensor for receiving a vial containing a controlled substance possessed by a patient. A processor receives a weight measured by the weight sensor. A communication circuit transmits the weight measured by the weight sensor to a remote server. The weight sensor may be mounted in a container having a first compartment and a second compartment. The first compartment has a first lid that is releasable without any lock. A second compartment has a second lid that is secured by a lock. The weight sensor is mounted inside the second compartment.

A monitoring system includes a weight sensor for receiving a vial containing a controlled substance possessed by a patient. A processor receives a weight measured by the weight sensor. A communication circuit transmits the weight measured by the weight sensor to a remote server. The weight sensor may be mounted in a container having a first compartment and a second compartment. The first compartment has a first lid that is releasable without any lock. A second compartment has a second lid that is secured by a lock. The weight sensor is mounted inside the second compartment.

The present invention relates to a compound of formula 2-phenyl-6-(1H-imidazol-1-yl) quinazoline (CR4056) or a pharmaceutically acceptable salt thereof for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid. The invention also relates to a composition or a pharmaceutical kit comprising a compound of formula 2-phenyl-6-(1Himidazol-1-yl) quinazoline (CR4056) or one of its pharmaceutically acceptable salts and at least one opioid for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid.

The present invention relates to a compound of formula 2-phenyl-6-(1H-imidazol-1-yl) quinazoline (CR4056) or a pharmaceutically acceptable salt thereof for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid. The invention also relates to a composition or a pharmaceutical kit comprising a compound of formula 2-phenyl-6-(1Himidazol-1-yl) quinazoline (CR4056) or one of its pharmaceutically acceptable salts and at least one opioid for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid.

A nitrogen-containing ring derivative regulator, a preparation method therefor and use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a G protein-coupled receptor regulator in the treatment or prevention of central nervous system diseases and/or mental diseases.

##STR00001##

Methods, pharmaceutical formulations and devices for the preventative treatment of incidental opioid overdose comprising the intramuscular or subcutaneous administration using an auto-injection device of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.

Methods, pharmaceutical formulations and devices for the preventative treatment of incidental opioid overdose comprising the intramuscular or subcutaneous administration using an auto-injection device of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.

A monitoring system includes a weight sensor for receiving a vial containing a controlled substance possessed by a patient. A processor receives a weight measured by the weight sensor. A communication circuit transmits the weight measured by the weight sensor to a remote server. The weight sensor may be mounted in a container having a first compartment and a second compartment. The first compartment has a first lid that is releasable without any lock. A second compartment has a second lid that is secured by a lock. The weight sensor is mounted inside the second compartment.

An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.